Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
Renal impairment is a common complication of multiple myeloma (MM). The estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula is the recommended method for the assessment of renal function in patients with MM with stabilized serum creatinine. In acute renal injury, the RIFLE (risk, injury, failure, loss and end-stage kidney disease) and Acute Renal Injury Network criteria seem to be appropriate to define the severity of renal impairment. Novel criteria based on eGFR measurements are recommended for the definition of the reversibility of renal impairment. Rapid intervention to reverse renal dysfunction is critical for the management of these patients, especially for those with light chain cast nephropathy. Bortezomib with high-dose dexamethasone is considered as the treatment of choice for such patients. There is limited experience with thalidomide in patients with myeloma with renal impairment. Thus, thalidomide can be carefully administered, mainly in the context of well-designed clinical trials, to evaluate if it can improve the rapidity and probability of response that is produced by the combination with bortezomib and high-dose dexamethasone. Lenalidomide is effective in this setting and can reverse renal insufficiency in a significant subset of patients, when it is given at reduced doses, according to renal function. The role of plasma exchange in patients with suspected light chain cast nephropathy and renal impairment is controversial. High-dose melphalan (140 mg/m(2)) and autologous stem-cell transplantation should be limited to younger patients with chemosensitive disease.
Dimopoulos
Meletios A
MA
University of Athens School of Medicine, Athens, Greece. mdimop@med.uoa.gr
Terpos
Evangelos
E
Chanan-Khan
Asher
A
Leung
Nelson
N
Ludwig
Heinz
H
Jagannath
Sundar
S
Niesvizky
Ruben
R
Giralt
Sergio
S
Fermand
Jean-Paul
JP
Bladé
Joan
J
Comenzo
Raymond L
RL
Sezer
Orhan
O
Palumbo
Antonio
A
Harousseau
Jean-Luc
JL
Richardson
Paul G
PG
Barlogie
Bart
B
Anderson
Kenneth C
KC
Sonneveld
Pieter
P
Tosi
Patrizia
P
Cavo
Michele
M
Rajkumar
S Vincent
SV
Durie
Brian G M
BG
San Miguel
Jésus
J
D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D005919:Glomerular Filtration Rate; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000150:complications* / Q000628:therapy; D011379:Prognosis; D011719:Pyrazines / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D013792:Thalidomide / Q000627:therapeutic use; D014182:Transplantation, Autologous
D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D008558:Melphalan